Revvity’s diagnostics unit, which provides testing tools for processes such as genetic screening, was a standout performer ‍in the quarter ended December 28, notching 7% organic growth and revenue of $390.1 million, ‍well ahead ⁠of the $377.7 million analysts ⁠had penciled in.